Abstract:During the last four decades, nuclear medicine has undergone enormous growth, and positron emission tomography (PET) has been in the driving seat for most of the time. 18F-fluorodeoxyglucose (18F-FDG) is the most widely used agent for the detection of hibernating myocardium and metabolically active cancer tissue. But its cost and limited availability are the main limitations. For a long time different researchers and groups of pharmacists have tried to label glucose with a cheaper and long-acting radionuclide like 99mTc. However, they failed to achieve this goal owing to the chemical complexity of 99mTc and the lack of maintaining the physiological activity of diagnostic compounds. A pre-targeting strategy based on strain-promoted [3 + 2] azide-alkyne cycloaddition (SPAAC) reaction was applied to solve this problem. Functional click synthons were synthesized: 2-azido-2-deoxy-d-glucose (GlucN3) as a glucose analogue, and N- (2- (2- (2- (bis (pyridin-2-ylmethyl) amino) ethoxy) ethoxy) ethyl-2- (6H-11,12-didehydrodibenzo [a,e] cycloocten-5-ylideneaminooxy) acetamide (C7) as a 99mTc(CO)3 labeling and azido-binding group. The results of biodistribution experiments in mice bearing S180 tumor show the relatively high tumor/blood ratio (up to 2.95) and tumor/muscle ratio (up to 6.37), and both of them decreases significantly in the glucose blocking experiment. It indicates that GlucN3 behaves similarly to glucose and that in vivo SPAAC reactions can occur effectively. It is supposed that this pre-targeting strategy can indeed enhance target specificity and may be used for glucose metabolism imaging in tumor diagnosis.

Novel 99Mtc-Labeled Glucose Derivative for Single Photon Emission Computed Tomography: A Promising Tumor Imaging Agent

Synthesis and biological evaluation of a &lt;sup&gt;99m&lt;/sup&gt;Tc-labeled glucose derivative for tumor imaging

Preparation and Bioevaluation of a Novel 99Mtc-Labeled Glucose Derivative Containing Cyclohexane As a Promising Tumor Imaging Agent

The Preparation and Execution of Exploratory Human Studies on Novel 99Mtc-Labeled Glucosamine Derivatives Containing Different Phenyl Isonitriles As Promising Tumor Imaging Agents.

99Mtc-Cn7dg: A Highly Expected SPECT Imaging Agent of Cancer with Satisfactory Tumor Uptake and Tumor-to-Nontarget Ratios

Novel 99mTc-Labeled Mannose Derivative as a Highly Promising Single Photon Emission Computed Tomography Probe for Tumor Imaging

Evaluation and Comparison of 99mtc‐labeled D‐glucosamine Derivatives with Different 99mtc Cores As Potential Tumor Imaging Agents

Evaluation of 99Mtc-Cn5dg As a Broad-Spectrum SPECT Probe for Tumor Imaging

Noninvasive Scintigraphic Detection of Tumor with 99Mtc-Dtpa-deoxyglucose: an Experimental Study.

Synthesis and Biodistribution of A New 99Mtc-Oxo Complex with Deoxyglucose Dithiocarbamate for Tumor Imaging

A pre-targeting strategy for imaging glucose metabolism using technetium-99m labelled dibenzocyclooctyne derivative.

Novel 99m Tc-labelled complexes with thymidine isocyanide: radiosynthesis and evaluation as potential tumor imaging tracers.

Synthesis and Evaluation of a 99m Tc-labeled Deoxyglucose Derivative As a Potential Agent to Target Tumor

Synthesis and Evaluation of 99Mtc–2-[(3-carboxy-1-oxopropyl)amino]-2-deoxy-d-glucose As a Potential Tumor Imaging Agent

99Tcmn-Dgdtc,a New Glucose Metabolic Agent,the Pharmacokinetics and Imaging Results

Synthesis and Biological Evaluation of a Novel (99m)tc Nitrido Radiopharmaceutical with Deoxyglucose Dithiocarbamate, Showing Tumor Uptake.

Novel [99mtcn]2+ Labeled EGFR Inhibitors As Potential Radiotracers for Single Photon Emission Computed Tomography (SPECT) Tumor Imaging

Synthesis and Biodistribution of Novel 99mtcn Complexes of Glucose Dithiocarbamate As Potential Probes for Tumor Imaging

Tumor Locating Property of ~(99)Tc~m-Mavgg-glucose

Radiolabeled Glucose Derivatives for Tumor Imaging Using SPECT and PET

Macrocyclic Triamine Derived Glucose Analogues for 99m Tc(CO)3 Labeling: Synthesis and Biological Evaluation As Potential Tumor-Imaging Agents.